A briefing for medical device, diagnostic, and life sciences company CEOs and CFOs preparing their 2Q26 earnings calls and 2H26 guidance
A DISCONNECT BETWEEN VALUATIONS AND FUNDAMENTALS
Medical technology stocks trade at approximately 15x next-twelve-months earnings—a 30% discount to the S&P 500 and a 30-year record valuation low. Yet industry fundamentals remain reasonably stable, and innovation is accelerating. Three temporary factors explain the rotation of capital out of the sector:
- The AI trade. Since November 2022, roughly 80% of the S&P 500’s performance has come from AI-related companies. Healthcare has been a source of capital, not a destination.
- Negative sentiment and record short positioning. J.P. Morgan’s Prime Book data reveals near-record short-vs-long positioning within the medical technology industry. Hedge funds have de-grossed meaningfully.
- Expectations reset for 2Q26 earnings. Medical technology management teams have spent months managing expectations downward. Investors have priced in weak results and potential guidance cuts.
However, signs of inflection are emerging. Market breadth has expanded, momentum has unwound from semiconductor and AI names, and hedge funds remain net short—creating technical rebound potential as generalist investors search for value.
RECENT NEWS
On July 14th, hospital operator HCA Healthcare pre-announced a deterioration in same-facility inpatient surgeries to a 2.3% year-over-year decline in 2Q26, while outpatient surgeries contracted 3.4%. HCA attributed the deterioration to Affordable Care Act exchange insurance plan disenrollment resulting from the expiration of federal government subsidies for premium payments. On July 16th, robotics surgery leader Intuitive Surgical reported a deceleration in U.S. procedure growth from 14% in 1Q26 to 12% in 2Q26, with Jamie Samath, the company’s CFO, stating, “Based on customer feedback, we believe there was a modest adverse impact to 2Q U.S. procedure growth from those patients impacted by the expiration of subsidies for ACA enhanced premiums. Looking at benign procedures, a subset of which can be deferred, we saw a slight moderation in procedure growth rate that started in Q1.”
These two announcements triggered market concern about systemic surgical volume collapse. But the reality is more nuanced, and more encouraging.
What the Data Actually Shows
Selective pressure, not systemic collapse. HCA’s hospitals are concentrated in states such as Florida and Texas, where Affordable Care Act exchange enrollment and reliance upon government subsidies were greatest due to those states’ prior decisions to not expand their Medicaid programs. As such, HCA witnessed a disproportionate surgical volume decline, concentrated in elective procedures among younger, uninsured patients disenrolling from ACA insurance plans. In contrast, HCA saw overall same-facility admissions rise 2.7% and Emergency Department (ED) visits rise 3.6%, indicating utilization is healthy for non-surgical and emergency care. Separately, Intuitive faces a disproportionate exposure to deferrable procedures, including benign gynecology, hernia repair, and bariatrics, which total more than half of Intuitive’s U.S. procedure volume.
Peer data validates selectivity. On July 15th, Johnson & Johnson reported MedTech segment sales growth of 3.6% in 2Q26, missing consensus expectations. But excluding one product line-specific headwind, namely Abiomed, JNJ’s 2-year comparable MedTech segment growth accelerated from 4.4% in 1Q26 to 4.9% in 2Q26. More critically, JNJ’s utilization proxy franchises, Orthopedics (+4.2%), Surgery (+2.3%), and Vision (+5.6%), all beat consensus expectations. Meanwhile, on July 16th, Abbott Laboratories reported Medical Devices segment growth of 8.4%, essentially stable with the 8.5% growth witnessed in 1Q26, and supporting management’s assertion of aggregate stability across procedure volumes.
Clinical diagnostics provide additional confidence. Within Abbott’s Diagnostic Products Segment, Core Laboratory sales grew 3.2% in 2Q26 and beat consensus on U.S. strength, while Cancer Diagnostics sales accelerated to 13.3% growth. Abbott’s CEO, Robert Ford, stated that testing volumes in the US “have held up very well, not seeing a decline, including in the states that we’ve seen the highest level of ACA disenrollment.” This diagnostic utilization demand, even where ACA coverage losses are most acute, validates stable demand for general healthcare utilization.
BASIS FOR CONFIDENCE: PROCEDURE VOLUME RESILIENCE, HOSPITAL CAPITAL EXPENDITURES AND REIMBURSEMENT STABILITY
Procedure volume commentary from management teams remains stable. Discussions with medical technology management teams suggest 2Q26 procedure volumes remained stable overall, with some surgeon groups and ambulatory surgery center operators reporting steady or slightly improving trends, supported by accelerating penetration of surgical robotics within ASCs. Tim Schmid, EVP and Worldwide Chairman of JNJ’s MedTech Segment, stated on the company’s 2Q26 conference call, “Based on what we’re seeing, we haven’t observed any meaningful impact on procedure volumes across our portfolio related to the ACA. And while we expect that the expiration of the Affordable Care Act subsidies may create some affordability pressures for a small cohort of patients, we do not expect this to translate into a material impact on demand for MedTech and procedures.”
Hospital capex budgets remain resilient. In its pre-announcement, HCA reiterated its 2026 capital expenditures guidance of $5.0-$5.5 billion. Further, a Bank of America survey of 53 hospital CFOs conducted June 29 – July 9, 2026, found a record high 77% of respondents expecting to increase capital expenditures over the next 12 months, with imaging equipment remaining the top spending priority (26%), followed by robotic surgery (21%) and hospital beds (19%). This directly benefits leading medical technology companies and is suggestive of strong acuity and surgical volumes.
Reimbursement environment continues to be stable and manageable. The most recent Outpatient Prospective Payment System rate proposals from Medicare remained positive, with many procedures receiving rate adjustments that exceeded historical trends. And hospitals are accelerating I.T. efforts to optimize workflows and collections. 43% of hospital CFO respondents noted implementation of AI for point-of-care applications and radiology, while 40% are considering implementation in billing, back-end administrative tasks, and revenue cycle management.
A POTENTIAL POCKET OF WEAKNESS: LIFE SCIENCE RESEARCH TOOLS
In contrast, the life science research industry may be facing more mixed trends.
A comprehensive Jefferies survey from June 24 – 30, 2026, found a muted outlook for purchases of genomic sequencing instruments. Among 50 biopharmaceutical, core lab, and academic institutions with combined annual sequencing budgets totaling more than $400 million, only 16% plan to purchase new bulk sequencing instruments and just 12% plan new single-cell or spatial genomic instrument purchases over the next 12 months. Additionally, 30% of surveyed labs are actively pursuing alternative financing strategies such as reagent rental agreements to obtain sequencing instruments, up from the 12% already implementing these models.
The consumables, software and services outlook is brighter. On a brighter note, within the 75%-90% of lab budgets being dedicated to consumables, rather than instruments, 86% of respondents noted multi-omic capabilities as important to their workflows, implying a favorable mix shift toward higher sophistication and spending. And AI adoption has reached 70% of surveyed labs, suggesting AI-enabled workflows and data analysis should support software and service revenue pull-through.
THE LESS-DISCUSSED TAILWIND: ACCELERATING INNOVATION
While procedural volume concerns dominate near-term investor focus, a mid-year FDA database review shows an encouraging trend of new product approvals across medical technology:
- 510(k) approvals: up 3% year-over-year in 1H26, implying ~3,240 for full year 2026
- Original PMAs: 23 in 1H26, up from just 13 in 1H25
- FDA Panel Tracks: 16 in 1H26, implying ~35 in full year 2026, up 17% year-over-year
Leading companies win share through product innovation. In an environment where procedural volume growth is selective and muted, product innovation is an independent driver of growth.
POSITIONING FOR YOUR EARNINGS CALL: PORTFOLIO EXPOSURE FRAMEWORK
As you prepare 2H26 guidance, ask yourself: What is your portfolio exposure?
If you have high exposure to elective procedures: Acknowledge any ACA-driven softness explicitly. Explain mitigation: pricing actions, product mix improvement, new product launches, or international expansion. This transparency builds credibility.
If you have high exposure to high-acuity, Medicare-driven, non-elective procedures: You can credibly claim stable volumes and defend against HCA concerns. Support this with utilization proxy data (your high-acuity segment performance) and explain why ACA reversal is less relevant to your business.
If you have high exposure to diagnostics: Emphasize resilience. Testing volumes are holding up even in highest ACA disenrollment states. Lead with diagnostic strength in your forward guidance.
The market respects executives who are specific about their exposure and transparent about their positioning. Generic claims about “stable procedures” without portfolio context lack credibility; portfolio-specific analysis backed by data is what investors are listening for.
THE BOTTOM LINE: SELECTIVE PRESSURE, NOT SYSTEMIC COLLAPSE
HCA’s 2Q26 pre-announcement revealed real selective pressure in elective procedures among younger, ACA-affected patients. But it did not validate systemic demand destruction. Hospital capital expenditures remain strong, diagnostic utilization is resilient, high-acuity procedures are stable, and innovation is accelerating.
Your 2H26 guidance should reflect this reality:
- Acknowledge where you see softness in ACA-affected electives
- Validate with your own data and utilization proxies
- Ground confidence in pipeline momentum and product launches
- Be specific about exposure and positioning, not generic about “stable markets”
The surgical volume decline is real in specific categories. But it is selective, not systemic. Your job is to show investors you understand exactly which parts of your business face headwinds and how you’re positioned to navigate them.
That’s the credibility you need to guide confidently through 2H26 and into 2027.
If you’d like to evaluate how your company’s exposure to elective, high-acuity, or diagnostic procedure volumes should shape your 2Q26 earnings narrative and 2H26 guidance, please contact Matt Willey, Managing Director within ICR’s Medical Technology and Diagnostics practice.
Publisher: Source link
